Altogether, these studies demonstrate the ambiguity surrounding the inhibition of GIPR and promoting GIP action to treat obesity and T2DM (these topics have been extensively reviewed by Killion et al. (2019), Campbell (2021), and Samms et al. (2020)). The gene discussed is GIPR; the disease is type 2 diabetes mellitus.